Algert Global LLC Sells 102,705 Shares of Quanterix Corporation $QTRX

Key Points

• Algert Global LLC has reduced its holdings in Quanterix Corporation by 68.6%, selling 102,705 shares and now owning approximately 0.12% of the company, valued at $306,000.
• Insider transactions include significant purchases by directors, with William P. Donnelly acquiring 93,113 shares and David R. Walt acquiring 131,869 shares, reflecting their confidence in the company's future.
• Quanterix reported a quarterly EPS of ($0.47), missing analyst expectations, and also announced a bleak FY 2025 guidance, with analysts predicting a consensus rating of "Hold."

Algert Global LLC decreased its holdings in Quanterix Corporation (NASDAQ:QTRX - Free Report) by 68.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,988 shares of the company's stock after selling 102,705 shares during the period. Algert Global LLC owned 0.12% of Quanterix worth $306,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after acquiring an additional 3,915 shares during the last quarter. Aaron Wealth Advisors LLC bought a new stake in Quanterix in the first quarter worth about $79,000. Allspring Global Investments Holdings LLC bought a new stake in Quanterix in the first quarter worth about $98,000. Canada Pension Plan Investment Board lifted its stake in Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock worth $108,000 after purchasing an additional 4,000 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in Quanterix in the fourth quarter worth about $108,000. Institutional investors own 86.48% of the company's stock.

Insider Buying and Selling

In other Quanterix news, Director William P. Donnelly acquired 93,113 shares of Quanterix stock in a transaction that occurred on Friday, June 6th. The stock was bought at an average price of $5.44 per share, with a total value of $506,534.72. Following the completion of the purchase, the director directly owned 139,094 shares of the company's stock, valued at approximately $756,671.36. This represents a 202.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David R. Walt acquired 131,869 shares of Quanterix stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average cost of $5.43 per share, with a total value of $716,048.67. Following the purchase, the director directly owned 1,628,802 shares of the company's stock, valued at $8,844,394.86. This represents a 8.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 463,113 shares of company stock worth $2,625,444. Corporate insiders own 6.90% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on QTRX. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Canaccord Genuity Group reissued a "hold" rating and issued a $5.00 price objective (down previously from $12.00) on shares of Quanterix in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $11.75.

Quanterix Price Performance

Shares of NASDAQ:QTRX traded up $0.01 during trading on Friday, reaching $4.55. 481,164 shares of the company were exchanged, compared to its average volume of 815,728. The firm has a market capitalization of $211.44 million, a PE ratio of -2.50 and a beta of 1.07. The business's fifty day simple moving average is $5.62 and its 200-day simple moving average is $5.97. Quanterix Corporation has a 12-month low of $4.05 and a 12-month high of $15.85.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.06). The company had revenue of $24.48 million for the quarter, compared to analysts' expectations of $29.73 million. Quanterix had a negative return on equity of 18.41% and a negative net margin of 56.04%. Quanterix has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Quanterix Corporation will post -0.98 EPS for the current fiscal year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.